Biocon’s Itolizumab Has Received The Drugs Controller General Of India’s (DCGI) Approval For Emergency Use In The Treatment Of Cytokine Release Syndrome (CRS) In Moderate To Severe ARDS (Acute Respiratory Distress Syndrome) Patients Due To COVID-19
How does it Work?
Itolizumab Mechanism Of Action
Itolizumab’s unique mechanism of action…
